Evidence map›Paper›PMID 41089710›Full record

ReviewJournal of clinical and translational hepatology2025

Portal Vein Thrombosis in Liver Cirrhosis: A Review of Risk Factors and Predictive Indicators.

Zhicheng Yang, Yongle Zhao, Honglin Chen, Han Zhang, Maoting Tan, Xianliu Li, Lingling Tao, Hongyun Zhao

Abstract readReview
In one paragraph

Review in Journal of clinical and translational hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. [Pathophysiological mechanisms of coagulation dysfunction associated with liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhicheng YangDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yongle ZhaoDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Honglin ChenDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Han ZhangDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Maoting TanDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xianliu LiDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Lingling TaoDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Hongyun ZhaoDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0009-0004-5824-3707

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Actively identifying the risk factors and predictive indicators associated with portal vein thrombosis (PVT) in liver cirrhosis (LC) can enable early diagnosis and treatment, which is of great significance for prolonging the survival of patients with LC. Hemodynamic disturbances, advanced LC, vascular endothelial injury, and mutations in thrombophilic genetic factors are established risk factors for PVT-LC. Venous dilatation and decreased blood flow velocity contribute to hemodynamic disturbances. The severity of LC can be assessed by the degree of portal hypertension, liver metabolic function biomarkers, and validated liver scoring systems. Iatrogenic interventions, endotoxemia, and metabolic syndrome may induce vascular endothelial injury and hypercoagulability, the latter of which can be quantified via coagulation-anticoagulation-fibrinolysis biomarkers. Mutations in thrombophilic genetic factors, such as Factor V Leiden, MTHFR C667T, and JAK2 V617F, disrupt coagulation-anticoagulation homeostasis and predispose patients to PVT-LC. This review specifically focuses on comprehensively delineating established risk factors and predictive indicators for PVT-LC, thereby providing a theoretical foundation for the construction of clinically applicable PVT predictive models to guide early interventions and improve the prognosis. Future research should further validate the associations between recently proposed risk factors and PVT-LC, while simultaneously establishing cutoff values for indicators with robust predictive value to construct a clinically applicable PVT prediction framework.

Indexed as

HemodynamicsHypertensionLiver cirrhosisMetabolic syndromePortal vein thrombosisPrediction algorithmsRisk factorsThrombophilia

Identifiers

PMID41089710
PMCPMC12515608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.